CGS-CIMB is initiating coverage on Hyphens Pharma with an ‘add’ call and target price of 36 cents.
This is expected to give the counter a 22% upside from its current 29.5 cent price, analyst Tay Wee Kuang writes in a Jan 6 report.
“We like Hyphens Pharma for its resilient business model and growing product portfolio as well as sales and distribution channels that will drive future earnings growth,” he notes.
For more insights on corporate trends...
Sign In or Create an account to access our premium content.
Subscription Entitlements:
Less than $9 per month
Unlimited access to latest and premium articles
3 Simultaneous logins across all devices
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)
